1. Search Result
Search Result
Results for "

theranostic

" in MedChemExpress (MCE) Product Catalog:

9

Inhibitors & Agonists

2

Peptides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-P10131

    Radionuclide-Drug Conjugates (RDCs) FAP Cancer
    3BP-3940 is a highly potent fibroblast activation protein (FAP)-targeting peptide for theranostics. 3BP-3940 is often coupled with radionuclides for tumor diagnosis and treatment .
    3BP-3940
  • HY-147057
    FAP-2286
    1 Publications Verification

    FAP Cancer
    FAP-2286 is a potent and selective FAP-binding peptide coupled to a radionuclide chelator with a mean IC50 value of 2.7 nM for binding to FAP. FAP-2286 can chelate radionuclides for imaging or therapeutic applications and has a strong effect on FAP-positive tumors. FAP-2286 can be used for FAP-positive tumor research .
    FAP-2286
  • HY-75706

    PARP Ligands for Target Protein for PROTAC Cancer
    N-Descyclopropanecarbaldehyde Olaparib is an analogue of Olaparib (HY-10162) containing DOTA moiety. N-Descyclopropanecarbaldehyde Olaparib is a PARP inhibitor used for synthesizing novel dual EGFR and PARP PROTAC, DP-C-4 . N-Descyclopropanecarbaldehyde Olaparib can be radiolabeled F-18 or fluorophore for positron emission tomography (PET) or optical imaging in several types of tumor .
    N-Descyclopropanecarbaldehyde Olaparib
  • HY-155485

    Others Cancer
    Abi-DZ-1 is a potential multifunctional theranostic agent via the HIF1α/OATPs Pathway. Abi-DZ-1 can be used in the research of tumor-targeted imaging and precision therapy .
    Abi-DZ-1
  • HY-142533

    Others Cancer
    HL-PEG2k is a second near-infrared Ru(II) polypyridyl complex. HL-PEG2k exhibits a wavelength bathochromic shift, enhanced photothermal conversion efficiency (41.77%), and an antineoplastic effect against glioma. HL-PEG2k displays a superior biocompatibility and thus can be a potential theranostic platform to combat the growth and recurrence of tumors .
    HL-PEG2k
  • HY-155278

    Others Cancer
    Anticancer agent 162 (compound 1d) is an effective anticancer theranostic agent. Anticancer agent 162 induces oncosis of Hela cells with lipophilicity and cytotoxicity selectivity .
    Anticancer agent 162
  • HY-P10648

    HER2-targeting peptide

    EGFR Cancer
    Herceptide (HER2-targeting peptide) is a HER2-targeting peptide, and can be further conjugated to the near-infrared fluorescent dye indocyanine green (HY-D0711) (ICG) for developing theranostic agents .
    Herceptide
  • HY-163077

    Reactive Oxygen Species Apoptosis Cancer
    Anticancer agent 175 (complex 1) ia a near-infrared (NIR) luminescent theranostic complex. Anticancer agent 175 induces ROS accumulation, mitochondrial damage, disruption of Bax/Bcl-2 equilibrium, and tumor cell apoptosis in HepG2 cell line .
    Anticancer agent 175
  • HY-155070

    DNA/RNA Synthesis Apoptosis Cancer
    SRE-II, an amide derivative, is an activatable photosensitizer for photodynamic cancer research with decreased fluorescence and photosensitizing capabilities. SRE-II can be further converted into the active photosensitizer SDU Red via carboxylesterase-catalyzed amide bond cleavage. SRE-II induces DNA damage and cell apoptosis in the presence of light. SRE-II can act as a promising theranostic agent for triple-negative breast cancer .
    SRE-II

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: